The role of bone marrow cells for JCV pathogenicity

Journal of Clinical Virology

Volumn 45, Issue 3, 2009, Pages 230-231

  Focosi, Daniele ^a   Maggi, Fabrizio ^a   Andreoli, Elisabetta ^a   Lanini, Letizia ^a   Ceccherini Nelli, Luca ^a   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bone marrow; JCV; Progressive multifocal leukoencephalopathy

Indexed keywords

EFALIZUMAB; NATALIZUMAB; RITUXIMAB;

B LYMPHOCYTE; BONE MARROW CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCYTOCHEMISTRY; JC VIRUS; LETTER; MULTIPLE SCLEROSIS; MYELOID LEUKEMIA; PATHOGENICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RISK FACTOR; VIRUS DETECTION;

BONE MARROW CELLS; HUMANS; JC VIRUS;

EID: 67649216537     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.05.023     Document Type: Letter

References (23)

1. Yousry T., Major E., Ryschkewitsch C., Fahle G., Fischer S., Hou J., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 9 (2006) 924-933
2. Carson K., Evens A., Richey E., Habermann T., Focosi D., Seymour J., et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project. Blood 113 (2009) 4834-4840
3. Advisory, F.P.H. Updated Safety Information about Raptiva (efalizumab); 2009. Available from: http://www.fda.gov/cder/drug/advisory/efalizumab.htm [cited Mar 16 2009].
4. Sobell J., and Weinberg J. Patient fatalities potentially associated with efalizumab use. J Drugs Dermatol 8 3 (2009) 215
5. Krumbholz M., Meinl I., and Kümpfel T. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71 (2008) 1350-1354
6. Roll P., Palanichamy A., Kneitz C., Dorner T., and Tony H.P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54 8 (2006) 2377-2386
7. Leandro M.J., Cambridge G., Ehrenstein M.R., and Edwards J.C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54 2 (2006) 613-620
8. Roll P., Dörner T., and Tony H. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 58 6 (2008) 1566-1575
9. Tan C., Dezube B., Bhargava P., Wuethrich C., Marzocchetti A., Autissier P., et al. JC virus in bone marrow of HIV+ and HIV- patients. 15th conference on retroviruses and opportunistic infections (CROI). Boston (2008)
10. Marzocchetti A., Wuthrich C., Tan C., Tompkins T., Bernal-Cano F., Bhargava P., et al. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J Neurovirol 14 (2008) 1-4
11. Anthony I.C., Crawford D.H., and Bell J.E. B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas. Brain 126 5 (2003) 1058-1067
12. Zohren F., Toutzaris D., Klarner V., Hartung H.-P., Kieseier B., and Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111 7 (2008) 3893-3895
13. Bonig H., Wundes A., Chang K., Lucas S., and Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 111 7 (2008) 3439-3441
14. Kim M., Kim S., Lee S., Sym S., Lee D., and Kim S. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP. Transfusion 47 8 (2007) 1447-1454
15. de Latour R., Chaoui D., Bourhis J., Belhocine R., Park S., Legrand O., et al. Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: a large multicenter comparative study in patients with malignant lymphoma. Leuk Lymphoma 48 5 (2007) 897-904
16. Monaco M., Atwood W., and Gravell M. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 70 (1996) 7004-7012
17. Monaco M.C.G., Sabath B.F., Durham L.C., and Major E.O. JC virus multiplication in human hematopoietic progenitor cells requires the NF-1-1 class D transcription factor. J Virol 75 20 (2001) 9687-9695
18. Syková E., and Jendelová P. Migration, fate and in vivo imaging of adult stem cells in the CNS. Cell Death Differ 14 7 (2007) 1336-1342
19. Lebwohl M., Tyring S., Hamilton T., Toth D., Glazer S., Tawfik N.W., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349 21 (2003) 2004-2013
20. Krueger J.G., Ochs H.D., Patel P., Gilkerson E., Guttman-Yassky E., and Dummer W. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomised, single blind study. J Invest Dermatol 128 11 (2008) 2615-2624
21. Coffey G., Fox J., Pippig S., Palmieri S., Reitz B., Gonzales M., et al. Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 33 5 (2005) 623-629
22. Bonnekoh B., Malykh Y., Böckelmann R., Bartsch S., Pommer A., and Gollnick H. Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy. Eur J Dermatol 16 6 (2006) 623-635
23. Focosi D., Fazzi R., Montanaro D., Emdin M., and Petrini M. Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: a clinical, neuroradiological and virological response after treatment with risperidone. Antiviral Res 74 2 (2006) 156-158